Navigation Links
Aladdin eToken First Strong Authentication Device to Achieve Certification from the SAFE-BioPharma Association
Date:12/10/2007

SAFE digital identity and signature standard being adopted worldwide by pharmaceutical and healthcare organizations as secure method of confirming

digital identities

CHICAGO, Dec. 10 /PRNewswire-FirstCall/ -- Aladdin Knowledge Systems (Nasdaq: ALDN), an information security leader specializing in authentication, software DRM and content security, today announced that the Aladdin eToken strong authentication device is the first hardware product to be certified under the recently established SAFE(TM) Product Certification Program (SPCP). The program is administered by SAFE-BioPharma Association, a fast-growing industry group that developed and manages the SAFE(TM) digital identity standard for the pharmaceutical and healthcare industries.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040416/CGALADDINLOGO)

Certification assures SAFE's members that the Aladdin eToken fully conforms to the SAFE digital identity and signature standard. SPCP imposes a rigorous self-testing process on SAFE Vendor Partner products in order to assess their compliance with the SAFE digital standard.

The SAFE Standard dramatically streamlines the pharmaceutical business and regulatory processes by allowing organizations to electronically verify the identities of all parties involved in numerous types of electronic transactions -- increasing security while also maximizing efficiency. Aladdin eToken's strong authentication technology allows SAFE members to easily apply the SAFE Standard to their day-to-day pharmaceutical business.

"We congratulate Aladdin on becoming the first SAFE Vendor Partner to use the new SAFE Product Certification Program to demonstrate that its product is compliant with the SAFE digital identity and signature standard. The company is to be congratulated for its vision and leadership," said Mollie Shields-Uehling, President and CEO, SAFE-BioPharma Association.

"As the first technology vendor to have a product certified by SAFE, Aladdin enjoys a leading role in providing strong authentication technologies to some of the most security-minded organizations in the industry," said Chen Arbel, vice president of strategic development at Aladdin. "By creating the keys on board the Aladdin eToken, we ensure the protection of data and prevent forgery in an industry that demands a consistent, secure method of confirming identities."

Aladdin eToken provides strong authentication for the pharmaceutical industry worldwide, meeting regulations such as those surrounding the European Union SSCD (Secure Signature Creation Device) that requires digital signatures to be hosted on a secure signature creation device such as Aladdin eToken.

About SAFE-BioPharma Association

SAFE-BioPharma Association is the non-profit association that created and manages the SAFE(TM) digital identity and digital signature standard for the pharmaceutical and healthcare industries. Through the SAFE standard, the association promotes interoperability and integration among researchers, vendors, regulators, clinicians and other pharmaceutical and healthcare stakeholders. The SAFE standard provides a secure, enforceable, and regulatory compliant way to verify the identities of parties involved in business-to-business and business-to-regulator electronic transactions. SAFE stands for "Signatures and Authentication For Everyone." The Association's members include Amgen, AstraZeneca, Bristol-Myers Squibb, Genzyme, GlaxoSmithKline, Johnson & Johnson, Merck, Pfizer, Procter & Gamble, Roche and Sanofi-Aventis. For more information, visit http://www.safe-biopharma.org.

About Aladdin eToken

Aladdin eToken is the world leader for USB-based authentication solutions. It provides strong user authentication and cost-effective password management solutions enabling organizations to easily and effectively expand business opportunities with secure network access, improve data security through enhanced encryption and digital signing, and reduce costs and vulnerabilities through superior password management. For more information, visit http://www.Aladdin.com/eToken.

About Aladdin

Aladdin Knowledge Systems' Software Rights Management products are the #1 choice of software developers and publishers to protect intellectual property, increase revenues, and reduce losses from software piracy. Aladdin eToken is the world's #1 USB-based authentication solution. The Aladdin eSafe secure Web gateway provides the most advanced protection against the latest Web-based threats and attacks. Aladdin has offices in 12 countries, a worldwide network of channel partners, and has won numerous awards for innovation. For more information, visit the Aladdin Web site at http://www.Aladdin.com.

SAFE(TM) is a trademark of SAFE-BioPharma Association. Any use of this trademark requires approval from SAFE-BioPharma Association.

(C)2007 Aladdin Knowledge Systems, Ltd. All rights reserved. eToken, Aladdin Knowledge Systems and the Aladdin logo are trademarks or registered trademarks of Aladdin Knowledge Systems, Ltd. All other product and brand names mentioned in this document are trademarks or registered trademarks of their respective owners.

Press Contact: Investor Relations Contact:

Matthew Zintel Erik Knettel / Andrea Costa

Zintel Public Relations Global Consulting Group

matthew.zintel@zintelpr.com aladdin@hfgcg.com

310.574.8888 646.284.9400


'/>"/>
SOURCE Aladdin Knowledge Systems
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. First biomarker discovered that predicts prostate cancer outcome
2. FDA Approves First Anti-Psychotic for Kids
3. Single-incision belly-button surgery to remove kidney performed first at UT Southwestern
4. First study examines newly-licensed RN work attitudes and intentions
5. Glades General Hospital First in Palm Beach County to Provide On-Site Electronic Birth Registration
6. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
7. Father and Daughter From Tanzania Receive Their First Medical Examination in Newport Beach
8. High and mighty: first common height gene identified by researchers behind obesity gene finding
9. APA Comments on FDAs First Approval of Medication to Treat Pediatric Schizophrenia and Bipolar Disorder
10. TriWest Creates First-of-its-Kind Partnership to Offer Military Leaders With Grief Support Program
11. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... Z-Medica, LLC, ... of Pittsburgh Medical Center (UPMC) will acquire QuikClot® Bleeding Control Kits® (BCK) to ... developed in association with efforts by the American College of Surgeons, U.S. Department ...
(Date:3/28/2017)... ... 28, 2017 , ... The Radiology Business Management Association (RBMA) is ... its new executive director. Mr. Still was selected through a careful months-long search by ... he is known to our members, has been a part of building the RBMA ...
(Date:3/28/2017)... ... 28, 2017 , ... Qualidigm , the mission-driven national ... a new, more expansive office space in order to accommodate its growing number ... office building in Wethersfield, Conn. located at 936 Silas Deane Highway and immediately ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... corrosive ions found in power plant water and steam. , Chlorides and sulfates ... and boilers, leading to extensive maintenance and unplanned shutdowns. Monitoring these ions at ...
(Date:3/28/2017)... ... March 28, 2017 , ... Columbus OH. Dr. Justin ... one of few medical professionals in the country to sit on the 2017 National ... Aesthetics, in just 2 years Dr. Harper helped propel the clinic from a small ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... Mass. , March 28, 2017 ... company developing innovative therapeutics that address significant unmet ... a patent from the Japan Patent Office (JPO) ... connective tissue growth factor (CTGF) for the treatment ... limited to skin fibrosis and proliferative retinopathy (Japanese ...
(Date:3/28/2017)... England , March 28, 2017 ... collaborative research with Cambridge ... Therapeutics Consortium   The Milner Therapeutics Institute today ... Consortium. Elysium Health has committed significant investment for collaborative projects ... the next four years. This is the first major research ...
(Date:3/27/2017)... March 27, 2017 Therapix ... pharmaceutical company specializing in the development of cannabinoid-based drugs, ... in the United States ... representing 40 ordinary shares of the Company, at ... Therapix has granted the underwriters a 45-day over-allotment ...
Breaking Medicine Technology: